Structure activity relationships of aristolochic acid analogues: Toxicity in cultured renal epithelial cells

Kidney International

Volumn 67, Issue 5, 2005, Pages 1797-1805

  Balachandran, Premalatha ^b   Wei, Feng ^b   Lin, Rui Chao ^b   Khan, Ikhlas A ^b   Pasco, David S ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b NONE

Author keywords

Aristolochic acid; Structure; Toxicity

Indexed keywords

10 HYDROXY 6 NITRO PHENANTHRO (3,4 DEXTRO) 1,3 DIOXOLO 5 CARBOXYLIC ACID; 10 METHOXY 6 NITRO PHENANTHRO (3,4 DEXTRO) 1,3 DIOXOLO 5 CARBOXYLIC ACID; 6 NITRO PHENANTHRO (3,4 DEXTRO 1,3 DIOXOLO 5 CARBOXYLIC ACID; 8 HYDROXY 6 NITRO PHENANTHRO (3,4 DEXTRO) 1,3 DIOXOLO 5 CARBOXYLIC ACID; 8 HYDROXY 9 METHOXY 6 NITRO PHENANTHRO (3,4 DEXTRO) 1,3 DIOXOLO 5 CARBOXYLIC ACID; 8 METHOXY 10 HYDROXY 6 NITRO PHENANTHRO (3,4 DEXTRO) 1,3 DIOXOLO 5 CARBOXYLIC ACID; 8 METHOXY 4 HYDROXY 6 NITRO PHENANTHRO (3,4 DEXTRO) 1,3 DIOXOLO 5 CARBOXYLIC ACID; 8 METHOXY 6 NITRO PHENANTHRO (3,4 DEXTRO) 1,3 DIOXOLO 5 CARBOXYLIC ACID; 8 METHOXY 9 HYDROXY 6 NITRO PHENANTHRO (3,4 DEXTRO) 1,3 DIOXOLO 5 CARBOXYLIC ACID; 8 METHOXY 9 HYDROXY PHENANTHRO (3,4 DEXTRO) 1,3 DIOXOLO 5 CARBOXYLIC ACID; 8 METHOXY PHENANTHRO (3,4 DEXTRO) 1,3 DIOXOLO 5 CARBOXYLIC ACID; ARISTOLOCHIC ACID; ARISTOLOLACTAM; CARBOXYLIC ACID DERIVATIVE; CASPASE 3; CASPASE 7; DYE; HYDROXYL GROUP; NITROPHENANTHRENE CARBOXYLIC; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARISTOLOCHIA; ARTICLE; CARCINOGENIC ACTIVITY; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DEMETHYLATION; ENZYME ACTIVATION; KIDNEY CELL; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 17744363092     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00277.x     Document Type: Article

References (69)

1. ROSENMUND H, REICHSTEIN T: Zur kenntnis der Aristolochiasaure. Pharm Acta Helv 18:243-261, 1943
2. RUCKER VG, CHUNG BS: Aristolochic acids from Aristolochia manshuriensis. Planta Med 27:68-71, 1975
3. PRIESTAP HA: Minor aristolochic acids from Aristolochia argentina and mass spectral analysis of aristolochic acids. Phytochemistry 26:519-529, 1987
4. MOSE JR: Further studies on aristolochia acid. Arzneimittelforschung 24:151-153, 1974
5. KLUTHE R, VOGT A, BATSFORD S: Double blind study of the influence of aristolochic acid on granulocyte phagocytic activity. Drug Res 32:443-445, 1982
6. MENGS U: Acute toxicity of aristolochic acid in rodents. Arch Toxicol 59:328-331, 1987
7. MENGS U: Tumour induction in mice following exposure to aristolochic acid. Arch Toxicol 61:504-505, 1988
8. VANHERWEGHEM JL, DEPIERREUX M, TIELEMANS C, et al: Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 341:387-391, 1993
9. VANHERWEGHEM LJ: Misuse of herbal remedies: The case of an outbreak of terminal renal failure in Belgium (Chinese herbs nephropathy). J Altern Complement Med 4:9-13, 1998
10. VANHAELEN M, VANHAELEN-FASTRE R, BUT P, VANHERWEGHEM JL: Identification of aristolochic acid in Chinese herbs. Lancet 343:174, 1994
11. COSYNS JP: Aristolochic acid and 'Chinese herbs nephropathy': A review of the evidence to date. Drug Saf 26:33-48, 2003
12. POURRAT J, MONTASTRUC JL, LACOMBE JL, et al: Nephropathy associated with Chinese herbal drugs. Two cases. Presse Med 23:1669, 1994
13. LORD GM, TAGORE R, COOK T, et al: Nephropathy caused by Chinese herbs in the UK. Lancet 354:481-482, 1999
14. TANAKA A, NISHIDA R, YOSHIDA T, et al: Outbreak of Chinese herb nephropathy in Japan: Are there any differences from Belgium? Intern Med 40:296-300, 2001
15. LI X, YANG L, YU Y: An analysis of the clinical and pathological characteristics of mu-tong (a Chinese herb) induced tubulointerstitial nephropathy. Zhonghua Nei Ke Za Zhi 40:681-687, 2001
16. MEYER MM, CHEN TP, BENNETT WM: Chinese herb nephropathy. Baylor U Med Center Proc 13:334-337, 2000
17. ARLT VM, STIBOROVA M, SCHMEISER HH: Aristolochic acid as a probable human cancer hazard in herbal remedies: A review. Mutagenesis 17:265-277, 2002
18. GILLEROT G, JADOUL M, ARLT VM, et al: Aristolochic acid nephropathy in a Chinese patient: Time to abandon the term "Chinese herbs nephropathy"? Am J Kidney Dis 38:E26, 2001
19. NORTIER JL, MARTINEZ MC, SCHMEISER HH, et al: Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 342:1686-1692, 2000
20. LORD GM, COOK T, ARLT VM, et al: Urothelial malignant disease and Chinese herbal nephropathy. Lancet 358:1515-1516, 2001
21. CHEN W, CHEN Y, LI A: The clinical and pathological manifestations of aristolochic acid nephropathy - The report of 58 cases. Zhonghua Yi Xue Za Zhi 81:1101-1105, 2001
22. COSYNS JP, DEHOUX JP, GUIOT Y, et al: Chronic aristolochic acid toxicity in rabbits: A model of Chinese herbs nephropathy? Kidney Int 59:2164-2173, 2001
23. ARLT VM, SCHMEISER HH, PFEIFER GP: Sequence-specific detection of aristolochic acid-DNA adducts in the human p53 gene by terminal transferase-dependent PCR. Carcinogenesis 22:133-140, 2001
24. SCHWETZ BA: From the Food and Drug Administration. JAMA 285:2705, 2001
25. LEBEAU C, ARLT VM, SCHMEISER HH, et al: Aristolochic acid impedes endocytosis and induces DNA adducts in proximal tubule cells. Kidney Int 60:1332-1342, 2001
26. LI W, CHOY DF, LAM MS, et al: Use of cultured cells of kidney origin to assess specific cytotoxic effects of nephrotoxins. Toxicol In Vitro 17:107-113, 2003
27. ZHOU X, YANG G, DAVIS CA, et al: Hydrogen peroxide mediates FK506-induced cytotoxicity in renal cells. Kidney Int 65:139-147, 2004
28. HANIGAN MH, DENG M, ZHANG L, et al: Stress response inhibits the nephrotoxicity of cisplatin. Am J Physiol Renal Physiol 2004 (in press)
29. GILLEROT G, GOFFIN E, MOULIN P, et al: Aristolochic acid nephropathy and the peritoneum: Functional, structural, and molecular studies. Kidney Int 64:1883-1892, 2003
30. GAO R, ZHENG F, LIU Y, et al: Aristolochic acid I-induced apoptosis in LLC-PK1 cells and amelioration of the apoptotic damage by calcium antagonist. Chin Med J (Engl) 113:418-424, 2000
31. SU Z, XU S, ZHENG F, LI Y: Aristolochic acid induced transdifferentiation and apoptosis in human tubular epithelial cells in vitro. Zhonghua Yu Fang Yi Xue Za Zhi 36:301-304, 2002
32. LIU MC, MARUYAMA S, MIZUNO M, et al: The nephrotoxicity of Aristolochia manshuriensis in rats is attributable to its aristolochic acids. Clin Exp Nephrol 7:186-194, 2003
33. THORNBERRY NA, LAZEBNIK Y: Caspases: Enemies within. Science 281:1312-1316, 1998
34. WU TS, OU LF, TENG CM: Aristolochic acids, aristolactam alkaloids and amides from Aristolochia kankauensis. Phytochemistry 36:1063-1068, 1994
35. JOU JH, CHEN S, WU T: Facile reversed-phase HPLC resolution and quantitative determination of aristolochic acid and aristolactam analogues in traditional Chinese medicine. J Liq Chrom Related Techn 26:3057-3068, 2003
36. BABICH H, BORENFREUND E: Structure-activity relationship (SAR) models established in vitro with the neutral red cytotoxicity assay. Toxicol In Vitro 1:3-9, 1987
37. BABICH H, BORENFREUND E: Neutral red assay for toxicology in vitro, in In Vitro Methods of Toxicology, edited by Watson RR, Boca Raton, FL, CRC Press Inc, 1992, pp 237-251
38. BABICH H, BORENFREUND E: Cytotoxicity of T-2 toxin and its metabolites determined with the neutral red cell viability assay. Appl Environ Microbiol 57:2101-2103, 1991
39. BORENFREUND E, PUERNER JA: Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol Lett 24:119-124, 1985
40. DEPIERREUX M, VAN DAMME B, VANDEN HOUTE K, VANHERWEGHEM JL: Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs. Am J Kidney Dis 24:172-180, 1994
41. COSYNS JP, JADOUL M, SQUIFFLET JP, et al: Chinese herbs nephropathy: A clue to Balkan endemic nephropathy? Kidney Int 45:1680-1688, 1994
42. HULL RN, CHERRY WR, WEAVER GW: The origin and characteristics of a pig kidney cell strain, LLC-PK. In Vitro 12:670-677, 1976
43. GRUNDEMANN D, BABIN-EBELL J, MARTEL F, et al: Primary structure and functional expression of the apical organic cation transporter from kidney epithelial LLC-PK1 cells. J Biol Chem 272:10408-10413, 1997
44. HOHAGE H, STACHON A, FEIDT C, et al: Regulation of organic cation transport in IHKE-1 and LLC-PK1 cells. Fluorometric studies with 4-(4-dimethylaminostyryl)-N-methylpyridinium. J Pharmacol Exp Ther 286:305-310, 1998
45. STIBOROVA M, FREI E, BREUER A, et al: Aristolactam I, a metabolite of aristolochic acid I, upon activation forms an adduct found in DNA of patients with Chinese herbs nephropathy. Exp Toxicol Pathol 51:421-427, 1999
46. PEZZUTO JM, SWANSON SM, MAR W, et al: Evaluation of the mutagenic and cytostatic potential of aristolochic acid (3,4-methylenedioxy-8-methoxy-10- nitrophenanthrene-1-carboxylic acid) and several of its derivatives. Mutat Res 206:447-454, 1988
47. SATO N, TAKAHASHI D, CHEN SM, et al: Acute nephrotoxicity of aristolochic acids in mice. J Pharm Pharmacol 56:221-229, 2004
48. SCHMEISER HH, SCHOEPE KB, WIESSLER M: DNA adduct formation of aristolochic acid I and II in vitro and in vivo. Carcinogenesis 9:297-303, 1988
49. PFAU W, SCHMEISER HH, WIESSLER M: N6-adenyl arylation of DNA by aristolochic acid II and a synthetic model for the putative proximate carcinogen. Chem Res Toxicol 4:581-586, 1991
50. NORTIER JL, VANHERWEGHEM JL: Renal interstitial fibrosis and urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). Toxicology 181:577-580, 2002
51. SCHMEISER HH, POOL BL, WIESSLER M: Mutagenicity of the two main components of commercially available carcinogenic aristolochic acid in Salmonella typhimurium. Cancer Lett 23:97-101, 1984
52. GOTZL E, SCHIMMER O: Mutagenicity of aristolochic acids (I, II) and aristolic acid I in new YG strains in Salmonella typhimurium highly sensitive to certain mutagenic nitroarenes. Mutagenesis 8:17-22, 1993
53. WANG B, ZHAO J, WANG, X, WANG L: Using receptor theory model to study the mechanism of toxicity of nitrobenzene derivatives. Huanjing Huaxue 23:80-84, 2004
54. BAILEY HC, SPANGGORD RJ: The relationship between the toxicity and structure of nitroaromatic chemicals. ASTM Special Technical Publication 802:98-107, 1983
55. CHUNG KT, MURDOCK CA, ZHOU Y: Effects of the nitro-group on the mutagenicity and toxicity of some benzamines. Environ Mol Mutagen 27:67-74, 1996
56. SIERRA-ALVAREZ R, LETTINGA G: The role of aromatic structure on methanogenic toxicity. Mededelingen van de Faculteit Landbouwwetenschappen, Universiteit Gent 54:1437-1447, 1989
57. KRUMBIEGEL G, HALLENSLEBEN J, MENNICKE WH, et al: Studies on the metabolism of aristolochic acids I and II. Xenobiotica 17:981-991, 1987
58. LI B, LI XM, ZHANG CY, et al: Cellular mechanism of renal proximal tubular epithelial cell injury induced by aristolochic acid I and aristololactam I. Beijing Da Xue Xue Bao 36:36-40, 2004
59. YANG, SS, CHU P, LIN MS, et al: Two clinical variants of Chinese herb nephropathy: Case reports and review of literature. J Med Sci 21:217-224, 2001
60. CRONIN AJ, MAIDMENT G, COOK T, et al: Aristolochic acid as a causative factor in a case of Chinese herbal nephropathy. Nephrol Dial Transplant 17:524-525, 2002
61. TANAKA A, NISHIDA R, SAWAI K, et al: Traditional remedy-induced Chinese herbs nephropathy showing rapid deterioration of renal function. Nippon Jinzo Gakkai Shi 39:794-797, 1997
62. TANAKA A, SHINKAI S, KASUNO K, et al: Chinese herbs nephropathy in the Kansai area: A warning report. Nippon Jinzo Gakkai Shi 39:438-440, 1997
63. PORTER AG, JANICKE RU: Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6:99-104, 1999
64. ZOU H, LI Y, LIU X, WANG X: An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 274:11549-11556, 1999
65. FERNANDES-ALNEMRI T, TAKAHASHI A, ARMSTRONG R, et al: Mch3, a novel human apoptotic cysteine protease highly related to CPP32. Cancer Res 55:6045-6052, 1995
66. COHEN GM: Caspases: The executioners of apoptosis. Biochem J 326:1-16, 1997
67. CHEN RH, CHANG TY: Involvement of caspase family proteases in transforming growth factor-beta-induced apoptosis. Cell Growth Differ 8:821-827, 1997
68. KIM SG, KIM SN, JONG HS, et al: Caspase-mediated Cdk2 activation is a critical step to execute transforming growth factor-beta1-induced apoptosis in human gastric cancer cells. Oncogene 20:1254-1265, 2001
69. BARNA G, SEBESTYEN A, CHINOPOULOS CC, et al: TGF beta 1 kills lymphoma cells using mitochondrial apoptotic pathway with the help of caspase-8. Anticancer Res 22:3867-3872, 2002